Abstract
The slowly (IKs) and rapidly (IKr) activating delayed rectifier K+ currents play important roles in cardiac ventricular repolarization. Compared with IKr, however, IKs has important distinguishing characteristics, including ß-adrenergic receptor stimulation and accumulation at rapid rates that may impart significant therapeutic relevance. Therefore, development of selective IKs inhibitors has been pursued as a strategy for providing potentially safer and more effective Class III antiarrhythmic agents and pharmacological tools for elucidating the normal physiological and potential pathological role of IKs in cardiac repolarization. We have identified a series of 3-Acylamino-1,4 benzodiazepines that are very potent and selective inhibitors of IKs. A representative compound, L-768,673 (1) (IC50∼8nM), has been extensively characterized for its pharmacologic activity. L-768,673 concentration-dependently prolongs action potential duration in a frequency-independent manner in vitro, but decreases transmural dispersion of refractoriness, a risk factor for arrhythmia induction. In conscious dogs, L-768,673 administered IV (0.3-100 μg / kg) and PO (0.03-1 mg / kg) elicits consistent but limited (5-15%) QTc prolongation, and increases ventricular refractory period more at fast than at slow pacing rates, indicating a “forward” rate-dependence in vivo. In an anesthetized canine model of anterior myocardial infarction, IKs blockers suppress the development of ischemic ventricular fibrillation at intravenous doses that minimally prolong the QT interval. IKs blockers display an interesting and intriguing profile of effects on cardiac electrophysiologic parameters that differ in remarkable ways from other selective Class III agents such as IKr blockers. It remains to be determined if these properties can be exploited clinically to provide more effective and safer treatment of cardiac arrhythmias.
Keywords: Ion channels, potassium current, heart, arrhythmia, Iks
Current Medicinal Chemistry
Title: Pharmacological Modulation of IKs: Potential for Antiarrhythmic Therapy
Volume: 11 Issue: 1
Author(s): Joseph J. Salata, Harold G. Selnick and Joseph J. Lynch Jr.
Affiliation:
Keywords: Ion channels, potassium current, heart, arrhythmia, Iks
Abstract: The slowly (IKs) and rapidly (IKr) activating delayed rectifier K+ currents play important roles in cardiac ventricular repolarization. Compared with IKr, however, IKs has important distinguishing characteristics, including ß-adrenergic receptor stimulation and accumulation at rapid rates that may impart significant therapeutic relevance. Therefore, development of selective IKs inhibitors has been pursued as a strategy for providing potentially safer and more effective Class III antiarrhythmic agents and pharmacological tools for elucidating the normal physiological and potential pathological role of IKs in cardiac repolarization. We have identified a series of 3-Acylamino-1,4 benzodiazepines that are very potent and selective inhibitors of IKs. A representative compound, L-768,673 (1) (IC50∼8nM), has been extensively characterized for its pharmacologic activity. L-768,673 concentration-dependently prolongs action potential duration in a frequency-independent manner in vitro, but decreases transmural dispersion of refractoriness, a risk factor for arrhythmia induction. In conscious dogs, L-768,673 administered IV (0.3-100 μg / kg) and PO (0.03-1 mg / kg) elicits consistent but limited (5-15%) QTc prolongation, and increases ventricular refractory period more at fast than at slow pacing rates, indicating a “forward” rate-dependence in vivo. In an anesthetized canine model of anterior myocardial infarction, IKs blockers suppress the development of ischemic ventricular fibrillation at intravenous doses that minimally prolong the QT interval. IKs blockers display an interesting and intriguing profile of effects on cardiac electrophysiologic parameters that differ in remarkable ways from other selective Class III agents such as IKr blockers. It remains to be determined if these properties can be exploited clinically to provide more effective and safer treatment of cardiac arrhythmias.
Export Options
About this article
Cite this article as:
Salata J. Joseph, Selnick G. Harold and Lynch Jr. J. Joseph, Pharmacological Modulation of IKs: Potential for Antiarrhythmic Therapy, Current Medicinal Chemistry 2004; 11 (1) . https://dx.doi.org/10.2174/0929867043456214
DOI https://dx.doi.org/10.2174/0929867043456214 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Side Effects of AAS Abuse: An Overview
Mini-Reviews in Medicinal Chemistry Ligands of Diltiazem Binding Site: An Overview of Some Chemotypes
Mini-Reviews in Medicinal Chemistry Anti-Inflammatory Therapy in Uveitis
Recent Patents on Inflammation & Allergy Drug Discovery Oxidative-Nitrosative Stress as a Contributing Factor to Cardiovascular Disease in Subjects with Diabetes
Current Vascular Pharmacology Extrahepatic Targets and Cellular Reactivity of Drug Metabolites
Current Medicinal Chemistry Cellular and Molecular Mechanisms of Low Cardiac Output Syndrome after Pediatric Cardiac Surgery
Current Vascular Pharmacology Antimicrobial Agents Deriving from Indigenous Plants
Recent Patents on Food, Nutrition & Agriculture Management of Blood Pressure and Heart Rate in Patients with Acute Stroke
Current Pharmaceutical Design Cardiac and Muscular Involvement in Idiopathic Inflammatory Myopathies: Noninvasive Diagnostic Assessment and the Role of Cardiovascular and Skeletal Magnetic Resonance Imaging
Inflammation & Allergy - Drug Targets (Discontinued) Neuronal and Vascular Oxidative Stress in Alzheimers Disease
Current Neuropharmacology Challenges in Managing Amniotic Fluid Embolism: An Up-to-Date Perspective on Diagnostic Testing with Focus on Novel Biomarkers and Avenues for Future Research
Current Pharmaceutical Biotechnology Salvaging the Ischemic Heart: Gi-Coupled Receptors in Mast Cells Activate a PKCε/ALDH2 Pathway Providing Anti-RAS Cardioprotection
Current Medicinal Chemistry Current Advances in L-DOPA and DOPA-Peptidomimetics: Chemistry, Applications and Biological Activity
Current Medicinal Chemistry Clinical Applications of Cardiac Multi-Slice Computed Tomography
Current Medical Imaging NOAC or warfarin for Atrial Fibrillation: does time in therapeutic range matter?
Recent Advances in Cardiovascular Drug Discovery (Discontinued) Treatment of Hypertensive Left Ventricular Hypertrophy
Current Pharmaceutical Design CTO in Contemporary PCI
Current Cardiology Reviews Tetrazole Derivatives as Promising Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Risk Factors for Heart Failure Progression and Outcomes
Current Cardiology Reviews Examination of QTc Values in Critically Ill Patients Diagnosed with Delirium and Prescribed Atypical Antipsychotics
Current Drug Safety